International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process: Q5E. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guide line.pdf. Accessed 21 Jan 2021.
European Medicines Agency. Guideline on Similar Biological Medicinal Products, CHMP/437/04 Rev 1. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 21 Jan 2021.
US Food and Drug Administration. Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009: Guidance for Industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.pdf. Accessed 21 Jan 2021.
Declerck P, Mourad FR, Rudd PM. Biosimilarity versus manufacturing change: two distinct concepts. Pharm Res. 2016;33:261–8. https://doi.org/10.1007/s11095-015-1790-3. Accessed 7 February 2021.
Jefferis R. Biologics: structural heterogeneity and immunogenicity. Br Jo Hosp Medi. 2017. https://doi.org/10.12968/hmed.2017.78.8.443. Accessed 7 February 2021.
Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr Pharm Biotechnol. 2008;9:468–81. https://doi.org/10.2174/138920108786786402. Accessed 10 March 2021.
Webster CJ, Wong A, Woollett GR. An efficient development paradigm for biosimilars. BioDrugs. 2019. https://doi.org/10.1007/s40259-019-00371-4. Accessed 7 February 2021.
Vezer B, Buzas Z, Sebeszta M, Zrubka Z. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin. 2016. https://doi.org/10.1185/03007995.2016.1145579. Accessed 21 January 2021.
US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 2015. https://www.fda.gov/media/82647/download. Accessed 21 Jan 2021.
Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2021;2012(11):527–40. https://doi.org/10.1038/nrd3746. Accessed 7 February 2021.
Medicines and Healthcare products Regulatory Agency (United Kingdom). MHRA guidance on the licensing of biosimilar products. 2020. https://www.gov.uk/government/consultations/mhra-draft-guidance-on-the-licensing-of-biosimilar-products/consultation-document-mhra-guidance-on-the-licensing-of-biosimilar-products. Accessed 2 Mar 2021.
Bielsky MC, Cook A, Wallington A, Exley A, Kauser S, Hay JL, Both L, Brown D. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020. https://doi.org/10.1016/j.drudis.2020.09.006. Accessed 2 March 2021.
Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019. https://doi.org/10.1007/s40259-019-00377-y. Accessed 21 January 2021.
National Academies of Sciences, Engineering, and Medicine 2020. Regulating Medicines in a Globalized World: The Need for Increased Reliance Among Regulators. Washington, DC: The National Academies Press. https://doi.org/10.17226/25594. Accessed 2 March 2021.
US Food and Drug Administration. Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products, April 1996. https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm122879.htm. Accessed 2 Mar 2021.
European Medicines Agency. Concept Paper on the Development of a Committee for Proprietary Medicinal Products (CPMP) Guideline on Comparability of Biotechnology-Derived Products, CPMP/BWP/1113/98. 1998. https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-committee-proprietary-medicinal-products-cpmp-guideline-comparability_en.pdf. Accessed 21 Jan 2021.
European Medicines Agency. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance – quality issues (revision 1). EMA/CHMP/BWP/247713/2012 May 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf. Accessed 7 Feb 2021.
European Medicines Agency. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CPMP/3097/02/Final. 2003. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-comparability-medicinal-products-containing-biotechnology-derived-proteins-active/bmwp/101695/06_en.pdf. Accessed 21 Jan 2021.
World Health Organization. Annex 2: Guidelines on evaluation of similar biotherapeutic products (SBPs). https://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf. Accessed 7 Feb 2021.
Health Canada. Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs. https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/information-submission-requirements-biosimilar-biologic-drugs-1.html. Accessed 7 Feb 2021.
Therapeutic Goods Administration (Australia). Biosimilar Medicines Regulation. https://www.tga.gov.au/sites/default/files/biosimilar-medicines-regulation.pdf. Accessed 7 Feb 2021.
Agência Nacional de Vigilância Sanitária –ANVISA (Brazil): Resolução da Diretoria Colegiada –RDC nº55, de 16 de Dezembro de 2010. http://antigo.anvisa.gov.br/documents/10181/2718376/%281%29RDC_55_2010_COMP.pdf. Accessed 21 Jan 2021.
Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, Seidl A, Schiestl M. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opin Biol Ther. 2021;2018(18):369–79. https://doi.org/10.1080/14712598.2018.1421169. Accessed 2 March 2021.
Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol. 2006;24:241–1252. https://doi.org/10.1038/nbt1252.. Accessed 7 February 2021.
Zhuang Y, Chen D, Sharma A, Xu Z. Risk-based comparability assessment for monoclonal antibodies during drug development: a clinical pharmacology perspective. AAPS J. 2018;20:109–22. https://doi.org/10.1208/s12248-018-0268-8. Accessed 7 February 2021.
Vandekerckhove K, Seidl A, Gutka H, Kumar M, Gratzl G, Keire D, Coffey T, Kuehne H. Rational selection, criticality assessment, and tiering of quality attributes and test methods for analytical similarity evaluation of biosimilars. AAPS J. 2018. https://doi.org/10.1208/s12248-018-0230-9. Accessed 2 March 2021.
European Medicines Agency. Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development, EMA/CHMP/138502/2017. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug_en.pdf. Accessed 21 Jan 2021.
van der Plas RM, Hoefnagel MHN, Hillege HL, Roes KCB. Pragmatic rules for comparability of biological medicinal products. Biologicals. 2019. https://doi.org/10.1016/j.biologicals.2019.11.002. Accessed 2 March 2021.
Creamer JS, Oborny NJ, Lunte SM. Recent advances in the analysis of therapeutic proteins by capillary and microchip electrophoresis. Anal Methods. 2021;2014(15):5427–49. https://doi.org/10.1039/C4AY00447G. Accessed 15 March 2021.
Rathore D, Faustino A, Schiel J, Pang E, Boyne M, Rogstad S. The role of mass spectrometry in the characterization of biologic protein products. Expert Rev Proteom. 2021;2018(15):431–49. https://doi.org/10.1080/14789450.2018.1469982. Accessed 15 March 2021.
Brinson RG, et al. Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics. MAbs. 2018. https://doi.org/10.1080/19420862.2018.1544454. Accessed 21 January 2021.
Lamanna WC, Mayer RE, Rupprecther A, Fuchs M, Higel F, Fritsch C, Vogelsang C, Seidl A, Toll H, Schiestl M, Holzmann J. The structure-function relationship of disulfide bonds in etanercept. Science Rep. 2017;7: 3951. https://www.nature.com/articles/s41598-017-04320-5. Accessed 21 Jan 2021.
Ghasriani H, Hodgson DJ, Brinson RG, McEwen I, Buhse LF, Kozlowski S, Marino JP, Aubin Y, Keire DA. Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars. Nat Biotechnol. 2016; 34: 139–41. https://www.nature.com/articles/nbt.3474. Accessed 15 Mar 2021.
Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2021;2011(29):310–2. https://doi.org/10.1007/s40259-020-00422-1. Accessed 19 March 2021.
Higel H, Seidl A, Sörgel F, Friess W. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur J Pharm Biopharm. 2021;2016(100):94–100. https://doi.org/10.1016/j.ejpb.2016.01.005. Accessed 15 March 2021.
Kim S, Song J, Park S, Ham S, Paek K, Kang M, Chae Y, Seo H, Kim H-C, Flores M. Drifts in ADCC-related quality attributes of Herceptin: Impact on development of a trastuzumab biosimilar. MAbs. 2017. https://doi.org/10.1080/19420862.2017.1305530. Accessed 15 March 2021.
Jae HL, Paek K, Moon JH, Ham S, Song J, Kim S. Biological Characterization of SB3, a trastuzumab biosimilar, and the influence of changes in reference product characteristics on the similarity assessment. BioDrugs. 2019. https://doi.org/10.1007/s40259-019-00362-5. Accessed 15 March 2021.
US Food and Drug Administration. Draft guidance for industry: comparability protocols for human drugs and biologics: chemistry, manufacturing, and controls information. Revision 1, 2016. https://www.fda.gov/media/97148/download. Accessed 6 Mar 2021.
European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins. EMEA/ CHMP/BMWP/301636/2008 Rev. 2018. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-clinical-development-similar-biological-medicinal-products-containing_en-1.pdf. Accessed 15 Mar 2021.
European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues. EMA/CHMP/ BMWP/403543/2010 May 2012. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf. Accessed 15 Mar 2021.
European Medicines Agency. Guidance on Similar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulating Factor. EMEA/CHMP/BMWP/ 31329/2005. 2006. https://www.ema.europa.eu/en/documents/scientific-guideline/annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins_en.pdf. Accessed 15 Mar 2021.
European Medicines Agency. Guideline on the Investigation of Bioequivalence, 2010. CPMP/EWP/QWP/1401/98 Rev. 1/Corr. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 21 Jan 2021.
US Food and Drug Administration. Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. 2016. https://www.fda.gov/media/88622/download. Accessed 6 Mar 2021.
Schiestl M, Ranganna G, Watson K, Jung B, Roth K, Capsius B, Trieb M, Bias P, Marechal-Jamil J. The path towards a tailored clinical biosimilar development. BioDrugs. 2020. https://doi.org/10.1007/s40259-020-00422-1. Accessed 2 March 2021.
Tu C-L, Wang Y-L, Hu T-M, Hsu L-F. Analysis of pharmacokinetic and pharmacodynamic parameters in EU versus US-licensed reference biological products: are in vivo bridging studies justified for biosimilar development? BioDrugs. 2019. https://doi.org/10.1007/s40259-019-00357-2. Accessed 5 March 2021.
US Food and Drug Administration. Division of Pulmonary, Allergy and Rheumatology Products (DPARP) sBLA 125057/394 Humira™ (adalimumab). Summary review for regulatory action. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125057Orig1s394SumR.pdf. Accessed 28 Mar 2021.
De Meulemeester J, Fedyk M, Jurkovica L, Reaume M, Dowlatshahi D, Stotts G, Shamy M. Many randomized clinical trials may not be justified: a cross-sectional analysis of the ethics and science of randomized clinical trials. J Clin Epidemiol. 2021;2018(97):20–5. https://doi.org/10.1016/j.jclinepi.2017.12.026.Accessed12February.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): General Considerations for Clinical Trials E8. 1997. https://database.ich.org/sites/default/files/E8_Guideline.pdf. Accessed 22 Mar 2021.
US Food and Drug Administration: Guidance for Industry: INDs for Phase 2 and Phase 3 Studies - Chemistry, Manufacturing, and Controls Information, 2003. https://www.fda.gov/media/70822/download. Accessed 22 Mar 2021.
Webster CJ, Woollett GR. A ‘global reference’ comparator for biosimilar development. BioDrugs. 2017. https://doi.org/10.1007/s40259-017-0227-4. Accessed 11 March 2021.
World Health Organization. WHO Guidelines on submission of documentation for the pilot procedure for prequalification of similar biotherapeutic products for rituximab and trastuzumab. 2020. https://www.who.int/medicines/regulation/02_Pilot_PQ_anticancer_fullPathway_20Feb2020.pdf?ua=1. Accessed 7 Feb 2021.
Rifkin R, Pourmahram T. Biosimilars Bring Value to Health Care. 2020. https://www.centerforbiosimilars.com/view/biosimilars-bring-value-to-health-care. Accessed 16 June 2021.
Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018; 7: 3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075809/. Accessed 26 Mar 2021.
Medicines for Europe. The Impact of Biosimilar Competition in Europe. May 2017. https://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf. Accessed 7 Feb 2021.
van Meer PJK, Ebbers HC, Kooijman M, Gispen-de Wied CC, Silva-Lima B, Moors EHM, Schellekens H. Contribution of animal studies to evaluate the similarity of biosimilars to reference products. Drug Discov Today. 2021;2015(20):483–90. https://doi.org/10.1016/j.drudis.2014.11.009. Accessed 7 Feb 2021